|
Synonyms: CGT-003 | CGT003 | E2F Duplex Decoy
Compound class:
Nucleic acid
Comment: Edifoligide is an oligonucleotide decoy that binds to and inhibits activity of E2F transcription factors that regulate expression of genes controlling smooth muscle cell proliferation. This is proposed as a mechanism to reduce the progressive neointimal hyperplasia that contributes to vein graft failure following coronary artery bypass graft (CABG) surgery [2-4].
|
| No information available. |
Summary of Clinical Use  |
| Edifoligide was progressed to phase 3 clinical evaluation, but it failed to show efficacy in preventing vein graft failure/stenosis [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT00042081 | Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures | Phase 3 Interventional | Anesiva, Inc. | Data from this study showed that edifoligide was not effective in preventing vein graft failure within 12 to 18 months after CABG. | 1 |
